California State Teachers Retirement System raised its stake in shares of Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) by 0.7% during the second quarter, Holdings Channel reports. The institutional investor owned 88,627 shares of the biopharmaceutical company’s stock after buying an additional 602 shares during the period. California State Teachers Retirement System owned approximately 0.09% of Lexicon Pharmaceuticals worth $1,272,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. BlackRock Group LTD raised its stake in Lexicon Pharmaceuticals by 56.9% in the first quarter. BlackRock Group LTD now owns 14,217 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 5,158 shares in the last quarter. A.R.T. Advisors LLC acquired a new stake in Lexicon Pharmaceuticals during the first quarter valued at about $174,000. Acrospire Investment Management LLC acquired a new stake in Lexicon Pharmaceuticals during the first quarter valued at about $211,000. Old Mutual Global Investors UK Ltd. acquired a new stake in Lexicon Pharmaceuticals during the second quarter valued at about $257,000. Finally, Fox Run Management L.L.C. acquired a new stake in Lexicon Pharmaceuticals during the second quarter valued at about $274,000.
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) traded down 1.01% on Friday, hitting $18.63. The stock had a trading volume of 487,345 shares. The firm’s market cap is $1.94 billion. The company’s 50 day moving average price is $16.22 and its 200 day moving average price is $14.27. Lexicon Pharmaceuticals Inc. has a 52-week low of $7.65 and a 52-week high of $19.62.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.04. The firm earned $20.10 million during the quarter, compared to analyst estimates of $12.36 million. Lexicon Pharmaceuticals had a negative return on equity of 9.03% and a negative net margin of 13.42%. Lexicon Pharmaceuticals’s revenue was up 5186.8% on a year-over-year basis. During the same period in the prior year, the business posted ($0.27) EPS. Analysts expect that Lexicon Pharmaceuticals Inc. will post ($1.54) EPS for the current year.
LXRX has been the subject of several research analyst reports. Needham & Company LLC reissued a “buy” rating and set a $21.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Monday, September 12th. Citigroup Inc. lifted their price objective on Lexicon Pharmaceuticals from $21.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, September 12th. Wedbush reissued a “buy” rating and set a $33.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Sunday, September 11th. Stifel Nicolaus lifted their price objective on Lexicon Pharmaceuticals from $25.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, August 5th. Finally, Zacks Investment Research raised Lexicon Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 3rd. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $20.93.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.
Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX).
Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.